Market closed
Adicet Bio/$ACET
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Adicet Bio
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its lead product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its lead preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.
Ticker
$ACET
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
143
Website
Adicet Bio Metrics
BasicAdvanced
$80M
Market cap
-
P/E ratio
-$1.55
EPS
1.70
Beta
-
Dividend rate
Price and volume
Market cap
$80M
Beta
1.7
52-week high
$3.77
52-week low
$0.89
Average daily volume
751K
Financial strength
Current ratio
10.638
Quick ratio
10.43
Long term debt to equity
7.054
Total debt to equity
8.603
Interest coverage (TTM)
-42,812.67%
Management effectiveness
Return on assets (TTM)
-33.50%
Return on equity (TTM)
-58.04%
Valuation
Price to book
0.38
Price to tangible book (TTM)
0.38
Price to free cash flow (TTM)
-0.797
Growth
Earnings per share change (TTM)
-53.42%
3-year earnings per share growth (CAGR)
-8.30%
What the Analysts think about Adicet Bio
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Adicet Bio stock.
Adicet Bio Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Adicet Bio Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Adicet Bio News
AllArticlesVideos
Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
Business Wire·2 weeks ago
Adicet Bio Presents Clinical Biomarker Data for Off-the-Shelf CAR T Cell Therapy in an Oral Session at the American College of Rheumatology (ACR) Convergence 2024
Business Wire·4 weeks ago
Adicet Bio to Participate in Upcoming Investor Conferences
Business Wire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Adicet Bio stock?
Adicet Bio (ACET) has a market cap of $80M as of December 14, 2024.
What is the P/E ratio for Adicet Bio stock?
The price to earnings (P/E) ratio for Adicet Bio (ACET) stock is 0 as of December 14, 2024.
Does Adicet Bio stock pay dividends?
No, Adicet Bio (ACET) stock does not pay dividends to its shareholders as of December 14, 2024.
When is the next Adicet Bio dividend payment date?
Adicet Bio (ACET) stock does not pay dividends to its shareholders.
What is the beta indicator for Adicet Bio?
Adicet Bio (ACET) has a beta rating of 1.7. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.